1. Pan-cancer and multiomics: advanced strategies for diagnosis, prognosis, and therapy in the complex genetic and molecular universe of cancer.
- Author
-
Campanharo CV, Dos Santos Silveira LV, Meira DD, Casotti MC, Altoé LSC, Louro ID, Gonçalves AFM, Machado AM, Paiva BS, de Souza Inocencio E, Rocha FVV, Pesente F, de Castro GSC, da Paixão JPDS, Bourguignon JHB, Carneiro JS, de Oliveira JR, de Souza Freire P, Zamprogno SB, Dos Santos Uchiya T, de Paula Rezende T, and de Pádua Sanders Medeiros V
- Abstract
The pan-cancer and multi-omics approach is motivated by the genetic and molecular complexity inherent in the varied types of cancer. This method presents itself as a crucial resource for advancing early diagnosis, defining prognoses and identifying treatments that share common bases between different forms of tumors. The aim of this article is to explore pan-cancer analysis in conjunction with multi-omics strategies, evaluating laboratory, computational, clinical procedures and their consequences, as well as examining the tumor microenvironment, epigenetics and future directions of these technologies in patient management. To this end, a literature review was conducted using PUBMED, resulting in the selection of 260 articles, of which 81 were carefully chosen to support this analysis. The pan-cancer methodology is applied to the study of this microenvironment with the aim of investigating its common characteristics through multiomics data. The development of new therapies depends on understanding the oncogenic pathways associated with different cancers. Thus, the integration of multi-omics and pan-cancer analyzes offers an innovative perspective in the search for new control points, metabolic pathways and markers, in addition to facilitating the identification of patterns common to multiple cancer types, allowing the development of targeted treatments. In this way, the convergence of multiomics and clinical approaches promotes a broad view of cancer biology, leading to more effective and personalized therapies., Competing Interests: Declarations. Conflict of interest: The authors declare no conflicts of interest. Ethical approval: Not applicable. Informed consent: Not applicable. Institutional review board: Not applicable., (© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).)
- Published
- 2024
- Full Text
- View/download PDF